Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$1.69 USD
-0.09 (-5.06%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.70 +0.01 (0.59%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Caribou Biosciences, Inc.'s return on equity, or ROE, is -62.35% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that CRBU has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CRBU 1.69 -0.09(-5.06%)
Will CRBU be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRBU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBU
Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates
Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know
CRBU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know
Other News for CRBU
CRBU forms Bollinger Band Squeeze on September 19
Is CRBU signaling a buying opportunity? Stochastic Buy Signal shows up after advancing 3.49%
Is CRBU getting ready to pop? Bollinger Band Squeeze shows up after sliding 4.44%
20 Day Moving Average Resistance appears for CRBU after 1.64% move
NR7 appears for CRBU after 1.67% move